Memo Therapeutics
Latest round
- Series C
Last raised
- May 2024
Total raised
- $98M
Investors
- 16
About Memo Therapeutics
Founded in 2012 by Christoph Esslinger, and based in Schlieren, Switzerland, Memo Therapeutics AG is a late-stage biotechnology company that operates as a developer of recombinant immunoglobulins and human-derived monoclonal antibodies for antibody and vaccine development. The firm's product AntiBKV, targets BK virus infections in kidney transplant patients. The firm also offers additional antibodies for cytomegalovirus and immuno-oncology targets, with a partnership with Ono Pharmaceutical. The company utilizes its proprietary DROPZYLLA® technology for antibody screening, leveraging immortal cell libraries and nanodroplet technology to identify and isolate effective antibodies.
Who invested in Memo Therapeutics
16 investors across 6 rounds
See all investors in Memo Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Memo Therapeutics
Who invested in Memo Therapeutics?
Memo Therapeutics has 16 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Memo Therapeutics raised?
Memo Therapeutics has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Memo Therapeutics last raise money?
Memo Therapeutics's most recent round on record is a Series C, in May 2024.
What does Memo Therapeutics do?
Founded in 2012 by Christoph Esslinger, and based in Schlieren, Switzerland, Memo Therapeutics AG is a late-stage biotechnology company that operates as a developer of recombinant immunoglobulins and human-derived monoclonal antibodies for antibody and vaccine development.
Where is Memo Therapeutics headquartered?
Memo Therapeutics is headquartered in Schlieren, Switzerland.
Which VCs invest in companies like Memo Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Memo Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Memo Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.